RxDoctor Payments DataLook up a doctor →

Michael Schweizer, MD

Medical Oncology · Seattle, WANPI 1942463450

Payments from drug & device makers

$27,445,747in general payments, 2019–2025

Across 658 payments — averaging $41,711 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$8.8M
  • Pfizer$8.1M
  • Merck$5.4M
  • Janssen Research & Development, LLC$3.7M
  • Novartis$543K
  • E.r. Squibb & Sons, L.L.C.$417K
  • plus $521K from 8 others
$22,480in research payments, 2019–2025

Across 29 payments — averaging $775.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$22K

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca16$8,776,897
Pfizer199$8,149,607
Merck31$5,375,463
Janssen Research & Development, LLC123$3,662,509
Novartis12$543,166
E.r. Squibb & Sons, L.L.C.6$416,966
Incyte Corporation236$183,549
Eli Lilly7$138,332
Bayer6$90,284
Genentech, Inc.11$55,194
Bristol Myers Squibb1$43,027
Sanofi7$5,878
Daiichi Sankyo Inc.2$4,050
Janssen Scientific Affairs, LLC1$825

How this compares

$27,445,747 in reported general payments places this provider in the 95th percentile of 162 medical oncology providers in Washington.

See all medical oncology providers in Washington

Medicare billing

Part B allowed, 2024
$66,610
Medicare patients
186
Services billed
461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →